Enterprise Therapeutics Secures $33.1M for Clinical Trials

Enterprise Therapeutics Ltd secures £26 million ($33.1 million USD) for the Phase 2a clinical trial of ETD001, targeting the ENaC ion channel in the airway epithelium. The funding aims to develop therapies for mucus congestion in respiratory diseases, particularly focusing on cystic fibrosis, chronic obstructive pulmonary disease, and severe asthma. The funding will support expansion into Italy and progression of other preclinical programs, with Dr Rob Woodman joining the Board of Directors.